Fig. 5

RocA and Mycro3 suppressed EMT and metastasis in pancreatic cancer cells in vitro and in vivo. a The suitable concentrations for treatment were initially determined to be 100 nmol/L (RocA) and 5000 nmol/L (Mycro3). b Treatment with 100 nmol/L RocA and 5000 nmol/L Mycro3, and either alone or in combination significantly inhibited the expression of miR-9 and c-MYC in AsPC-1 cells. c AsPC-1 cells were treated with DMSO, RocA (100 nM), Mycro3 (5000 nM), and combination treatment for 4 h and evaluated by CCK8 assay. It showed that there were no significant differences of the death ratio among each treatment group. d Treatment with 100 nmol/L RocA and 5000 nmol/L Mycro3 either alone or in combination significantly decreased the migratory and invasive capabilities of AsPC-1 cells. There were no significant differences among the treatment groups. e RocA significantly decreased the metastasis level of AsPC-1 cells in vivo whereas Mycro3 and the combination treatment did not. f RocA significantly suppressed subcutaneous tumor xenograft growth. g Western blot results showed that RocA notably decreased the expression of eIF4A1, c-MYC, and snail, but increased the expression of E-cadherin in subcutaneous tumor grafts. *P < 0.05, **P < 0.01, ***P < 0.001, NS: no statistical significance